CIP2A confirms its prognostic value in triple-negative breast cancer.
Cristóbal I, Zazo S, Torrejón B, Pedregal M, Madoz-Gúrpide J, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Rojo F.
Cristóbal I, et al. Among authors: torrejon b.
Oncogene. 2017 Jun 8;36(23):3357-3358. doi: 10.1038/onc.2016.474. Epub 2017 Jan 9.
Oncogene. 2017.
PMID: 28068327
No abstract available.